We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

16 hedge funds and large institutions have $4.16M invested in Kiora Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.48% less ownership

Funds ownership: 49.47% → 41.98% (-7.5%)

16% less funds holding

Funds holding: 19 → 16 (-3)

23% less capital invested

Capital invested by funds: $5.38M → $4.16M (-$1.21M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
+$12.7K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.09K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$662K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$41.7K
3
Citadel Advisors
Citadel Advisors
Florida
-$37K
4
SM
Sabby Management
Florida
-$18.3K
5
RA
Rosalind Advisors
Ontario, Canada
-$17.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$850K – – –
RA
2
Rosalind Advisors
Ontario, Canada
$827K -$17.3K -5,000 -2%
NCM
3
Nantahala Capital Management
Connecticut
$697K – – –
SCM
4
Stonepine Capital Management
Oregon
$663K -$4.94K -1,430 -0.7%
ACM
5
ADAR1 Capital Management
Texas
$661K +$12.7K +3,670 +2%
VCIM
6
Velan Capital Investment Management
Georgia
$403K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$53.8K +$5.09K +1,474 +10%
BlackRock
8
BlackRock
New York
$5.3K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$3.98K -$2.59K -749 -38%
NA
10
NewEdge Advisors
Louisiana
$73 – – –
Bank of America
11
Bank of America
North Carolina
$66 -$7 -2 -9%
US Bancorp
12
US Bancorp
Minnesota
$26 – – –
UBS Group
13
UBS Group
Switzerland
$7 -$1.22K -352 -99%
AWM
14
Activest Wealth Management
Florida
$7 – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$6 -$3 -1 -33%
SS
16
SBI Securities
Japan
$3 +$3 +1 New
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
– -$662K -180,780 Closed
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
– -$41.7K -11,382 Closed
Citadel Advisors
19
Citadel Advisors
Florida
– -$37K -10,114 Closed
SM
20
Sabby Management
Florida
– -$18.3K -5,000 Closed

KPRX Hedge Fund Activity: Q4 2024 in Review

16 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2024, worth a combined $4.16M — down 23% from $5.38M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of KPRX and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was ADAR1 Capital Management, adding an estimated $12.7K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $662K sold.

  • 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2024, down from 19 in Q3 2024.
  • Funds reported $4.16M of Kiora Pharmaceuticals stock for Q4 2024, down 23% quarter-over-quarter.
  • 1 fund opened new Kiora Pharmaceuticals positions in Q4 2024 and 4 closed out, a net change of -3 holders.
  • The largest Kiora Pharmaceuticals buyer in Q4 2024 was ADAR1 Capital Management, an estimated $12.7K added.
  • The largest Kiora Pharmaceuticals seller in Q4 2024 was Alyeska Investment Group, an estimated $662K sold.

Based on aggregated 13F filings for Q4 2024.